Market Overview

UPDATE: Goldman Sachs Raises PT on AmerisourceBergen Corp. Following ABC/WAG Deal

Related ABC
Morgan Stanley Sees Drug Pricing Still An Overhang For Diplomat, AmerisourceBergen
AmerisourceBergen Announces New Special Share Repurchase Program to Further Enable Execution of Warrant Hedging Strategy
Morgan Stanley's Risinger cools to some big biotechs (Seeking Alpha)

In a report published Wednesday, Goldman Sachs analyst Robert P. Jones reiterated a Neutral rating on AmerisourceBergen Corp. (NYSE: ABC), and raised the price target from $48.00 to $52.00.

In the report, Jones noted, “On our new estimates, ABC now trades at a 2x P/E multiple premium to MCK and CAH. While some may argue that ABC's valuation is justifiable given growth and support to numbers from the announced WAG deal, we find it difficult to overcome at current levels and maintain our Neutral rating. We still see the greatest risk/reward in MCK trading essentially at parity with CAH on our CY14, given (1) a more attractive growth profile through CY2014 after CAH's loss of WAG, (2) pending CVS contract renewals, which pose a risk for both, but greater for CAH at 31% of sales, versus MCK at 16%, and (3) a more attractive Specialty footprint - a differentiator in outer years.”

AmerisourceBergen Corp. closed on Tuesday at $50.06.

Latest Ratings for ABC

Oct 2015Morgan StanleyDowngradesEqual-weightUnderweight
Jul 2015KeyBancMaintainsOverweight
May 2015Cowen & CompanyDowngradesOutperformMarket Perform

View More Analyst Ratings for ABC
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings


Related Articles (ABC)

View Comments and Join the Discussion!

Get Benzinga's Newsletters